Gakuto Ogawa
Japan Clinical Cancer Research Organization(JP)
Publications by Year
Research Areas
Gastric Cancer Management and Outcomes, Esophageal Cancer Research and Treatment, Cholangiocarcinoma and Gallbladder Cancer Studies, Metastasis and carcinoma case studies, Breast Cancer Treatment Studies
Most-Cited Works
- → Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial(2020)210 cited
- → A nonrandomized, single-arm confirmatory trial of expanded endoscopic submucosal dissection indication for undifferentiated early gastric cancer: Japan Clinical Oncology Group study (JCOG1009/1010)(2020)107 cited
- → Gamma loop dysfunction in the quadriceps femoris of patients who underwent anterior cruciate ligament reconstruction remains bilaterally(2006)74 cited
- → 1616O Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): A multicentred, randomized, open-label, three-arm, phase II/III trial(2023)51 cited
- → Factors associated with technical difficulty of endoscopic submucosal dissection for early gastric cancer that met the expanded indication criteria: post hoc analysis of a multi-institutional prospective confirmatory trial (JCOG0607)(2019)45 cited
- → A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial(2021)35 cited
- → Gastric cancer is highly prevalent in Lynch syndrome patients with atrophic gastritis(2020)23 cited
- → A randomized controlled trial comparing primary tumor resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group study JCOG1017.(2023)17 cited
- → Stage III disease of ovarian, tubal and peritoneal cancers can be accurately diagnosed with pre-operative CT. Japan Clinical Oncology Group Study JCOG0602(2020)16 cited
- → A single-arm confirmatory study of definitive chemoradiotherapy (dCRT) including salvage treatment in patients (pts) with clinical (c) stage II/III esophageal carcinoma (EC) (JCOG0909).(2018)16 cited